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A b s t r a c t
Introduction: Atherosclerotic carotid artery stenosis (CS)-related strokes are a significant overall stroke burden contributor.
Aim: To evaluate the effect of surgical (carotid endarterectomy – CEA) vs. percutaneous (neuroprotected carotid artery stenting 
– CAS) carotid revascularization on health-related quality of life (HRQoL) in stroke survivors: analysis controlled for major HRQoL 
determinants beyond strokes.
Material and methods: Our database of 856 carotid revascularization procedures (48.7% symptomatic CS) performed over 
3 years showed 42 pairs (CEA-CAS) of right hemispheric stroke patients matched for age, sex, marital and educational status, hyper- 
tension, heart failure and diabetes, who underwent uneventful carotid revascularization, experienced no major adverse clinical 
events, and completed the Short Form Outcome Study (SF-36) questionnaire within 7 days before, 14 days after, 6 months after, 
and 12 months after carotid revascularization.
Results: Baseline HRQoL was low and similar in both groups (30.8 ±4.6% vs. 29.1 ±3.9%, p = 0.68; data given for CEA vs. CAS). 
National Institute of Health Stroke Scale chronic severity was 5.4 ±2.8 vs. 5.9 ±3.1 (p = 0.44). Revascularization was associated with 
a major HRQoL improvement, that was significantly greater in CAS (60.4 ±9.2% vs. 71.5 ±6.2%, p < 0.001). At 6 months the CEA-CAS 
difference was narrower (70.7 ±9.7% vs. 74.6 ±5.9%, p = 0.026), becoming statistically insignificant at 12 months (72.6 ±6.7% vs. 
75.1 ±5.1%, p = 0.062). The early CEA-CAS difference was driven by less bodily pain and better physical functioning/role-physical 
plus better role-emotional and higher general well-being scores in CAS (p < 0.05).
Conclusions: Carotid revascularization has a major positive impact on stroke survivor patient-reported HRQoL. The improve-
ment is initially greater in CAS, with the remaining difference small at 12 months and statistically insignificant. 
Key words: symptomatic carotid stenosis, stroke, carotid endarterectomy, carotid artery stenting, health-related quality of life, 
SF-36, physical functioning, mental functioning.
S u m m a r y
In stroke survivors matched for stroke severity and for major health-related quality of life (HRQoL) determinants beyond 
stroke, carotid revascularization has a major positive impact on patient-reported HRQoL. The early post-revascularization  
improvement is greater with carotid artery stenting (CAS), due to less bodily pain and better physical functioning and role- 
physical as well as better role-emotional and higher general well-being scores. At 6 months the remaining carotid endar-
terectomy (CEA)-CAS difference is small – to become not statistically significant at 12 months. As surgeons are increasingly 
performing endovascular procedures, these findings may affect – on top of major adverse clinical events associated with 
CEA and CAS – the patient and physician preferences, though they require confirmation in larger cohorts and multi-centre 
settings. In essence, our results show that in survivors of CS-related stroke, carotid revascularization is associated with 
a significant improvement in patient-perceived HRQoL, supporting its use in stroke survivors who were not lucky enough to 
benefit from carotid revascularization to prevent the devastating event.
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Introduction
Ischaemic stroke has a profound impact on health-re-
lated quality of life (HR-QoL) [1]. Despite the progress 
in pharmacotherapy and increasing penetration of ath-
erosclerosis-modifying drugs such as statins and angio-
tensin-converting enzyme inhibitors [2], atherosclerotic 
carotid artery stenosis (CS) continues to be a major mod-
ifiable risk factor of ischaemic stroke [3]. With 15–25% 
of ischaemic strokes occurring in relation to CS [3, 4], the 
CS contributes importantly to the individual and social 
burden of stroke disability [3].
Carotid revascularization, either surgical (carotid 
endarterectomy – CEA) or endovascular (neuroprotected 
carotid artery stenting – CAS), has been demonstrated 
to reduce stroke risk in both symptomatic (i.e., after cere-
bral/retinal stroke or transient ischaemic attack) and as-
ymptomatic subjects with CS [2, 4] but there is an ongo-
ing debate on whether and which patient subsets should 
be revascularized [2, 4, 5]. Pharmacotherapy may reduce 
stroke risk but is not, on its own, sufficient to prevent 
strokes, because CS-related strokes continue to occur, in 
vascular clinic patients, at a yearly rate of 2.5–2.9% de-
spite guideline-based pharmacotherapy [2, 5]. One sur-
prising view is that despite the recent large-scale (n = 
3120 patients) level-1 evidence from the Asymptomatic 
Carotid Surgery Trial (ACST-1) that demonstrated a pro-
found (≈ 50%) stroke reduction with CS revasculariza-
tion irrespective of lipid-lowering pharmacotherapy [6], 
revascularization “should” be limited, in principle, to pa-
tients after occurrence of symptoms of cerebral (or reti-
nal) ischaemia such as transient ischaemic attack (TIA) or 
stroke [4]. According to this concept, effective treatment 
becomes provided, to many stroke survivors, already too 
late because the cerebral damage that has occurred is 
largely irreversible [1, 7–9]. Thus although CS revascular-
ization does have a role in secondary stroke prevention, 
its role in reducing the post-stroke physical disability is 
limited once a major stroke-related disability has already 
occurred [1, 2, 7–10]. 
It is debated not only whether and which CS patients 
should be revascularized but also which of the two re-
vascularization methods, CEA or CAS, should applied 
as a  first-line interventional treatment modality. Out-
comes of this debate are driven, in principal, by which 
clinical endpoints are (subjectively) considered to be 
more important than others. A  recent meta-analysis of 
6526 patients from 5 trials with a  mean follow-up of 
5.3 years showed that while the composite outcome 
of periprocedural death, stroke, myocardial infarction 
(MI), or non-periprocedural ipsilateral stroke was not 
significantly different between CAS or CEA (OR = 1.22; 
95% CI: 0.94–1.59), the risk of any periprocedural stroke 
plus non-periprocedural ipsilateral stroke was higher with 
first-generation carotid artery stents (CAS) (OR = 1.50; 
95% CI: 1.22–1.84) [11]. The higher stroke risk with CAS 
was mostly attributed to periprocedural minor stroke; 
OR = 2.43; 95% CI: 1.71–3.46) [11]. The CAS, however, 
was associated with a significantly lower risk of peripro-
cedural MI (OR = 0.45; 95% CI: 0.27–0.75), cranial nerve 
palsy (OR = 0.07; 95% CI: 0.04–0.14) and the compos-
ite outcome of death, stroke, MI, or cranial nerve palsy 
during the periprocedural period (OR = 0.75; 95% CI: 
0.60–0.93) [11]. Indeed, 10-year data from the Carotid 
Revascularization Endarterectomy Versus Stenting Trial 
(CREST-1) have recently shown that patients with peripro-
cedural stroke were at 1.74× the risk of death compared 
with those without stroke (adjusted hazard ratio = 1.74; 
95% CI: 1.21–2.50; p < 0.003) while patients with MI were 
at 3.61× increased risk of death compared with those 
without MI (adjusted hazard ratio =3.61; 95% CI: 2.28–
5.73; p < 0.0001) [12]. Stroke, however, has a higher nega-
tive impact on HR-QoL than MI or heart failure [1, 12–15].
There is increasing understanding that quality of life 
(rather than major adverse clinical endpoints in isolation) 
should be receiving more attention in contemporary eval-
uation of the overall clinical evidence on CEA and CAS, 
and in determining the relative place of each in everyday 
clinical practice. Unfortunately, data on health-related 
quality of life (HR-QoL) after CEA and CAS are limited. In 
particular, no comparison of HR-QoL evolution in symp-
tomatic CS patients treated with CEA vs CAS has been 
performed so far. 
Aim
We have evaluated the effect of CS revascularization 
by CEA vs. CAS on HR-QoL in stroke survivors by perform-
ing a cross-sectional analysis controlled for major (other 
than stroke) HR-QoL determinants, and controlled for 
the subject’s ability to adequately express their views by 
assessing subjects with their ischaemic cerebral infarct 
location in the non-dominant hemisphere. 
Material and methods
We performed a  cross-sectional analysis based on 
856 carotid revascularization procedures performed over 
3 years in the Department of Vascular Surgery and Endo-
vascular Interventions at John Paul II Hospital in Krakow. 
Symptomatic carotid stenosis (n = 417) accounted for 
48.7% of the total carotid revascularization procedures. 
The decision on which particular method of carotid re-
vascularization (CEA vs. CAS) to apply in which patient 
was, in general, guideline-based [4], but the patient and 
physician preference was also considered. Eversion CEA 
was conducted under general anaesthesia with brain 
protection using shunt devices. CAS was performed us-
ing conventional carotid stents and endovascular cere-
bral protection devices according to the “tailored CAS” 
algorithm [16] under local anaesthesia in the access site 
(typically groin). CEA and CAS were performed by expe-
rienced vascular surgeons and interventionalists who 
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had previously performed a minimum of 100 procedures. 
During the study period there were 437 CEAs and 419 
CAS procedures. 
Health-related quality of life (HR-QoL) was assessed, 
as part of the Quality of Life in Carotid Revascularization 
Project carried out in our institution, using standardized 
questionnaires. The questionnaires were administered in 
written fashion. Medical Outcomes Study Short Form 36 
(SF-36) [17] was used to determine the patients’ percep-
tion of their health status. SF-36 is a 36-item, commonly 
used health survey that assesses eight dimensions of 
health status, including physical health (4 domains) and 
mental health (4 domains), with a weighted “value” of 
complaints (and their severity) in each domain (physical 
functioning, role-physical, bodily pain, and general health 
in the physical health section; vitality, social functioning, 
role-emotional and well-being in the mental health sec-
tion) [17]. SF-36 has been validated to evaluate HR-QoL 
in stroke patients [1, 15] as well as in patients with CS 
subjected to revascularization [13, 14, 18]. Scores for the 
SF-36 are in the range 0–100; a difference of 5–10 points 
is considered a  clinically important change for an indi-
vidual, whereas smaller differences may be important 
for group comparisons [13, 17]. Moreover, the SF-36 pro-
vides a summary scale (“total”) for overall physical and 
mental health, for which individual differences of 2.5–5 
points are considered statistically significant [13, 17]. In 
the present investigation, SF-36 outcomes were present-
ed in a fashion where higher scores correspond to fewer 
complaints (and/or their smaller severity), indicating bet-
ter health status and higher quality of life [13, 17, 18].
The patients were encouraged to fill in a  SF-36 
questionnaire (Polish language version [19, 20]) with-
in 7 days before carotid revascularization, and during 
the three scheduled post-revascularization visits in the 
vascular outpatient clinic; 14 days after, 6 months after, 
12 months after CEA or CAS. Neurologic examination 
was performed at baseline, prior to discharge and at 
12 months. The return rate of completed SF-36 forms was 
94.1% at baseline, 85.8% at 14 days, 81.5% at 6 months, 
and 77.9% at 12 months.
To evaluate the effect of CS revascularization by CEA 
vs. CAS on HR-QoL in stroke survivors, we controlled for 
not only the size of neurologic deficit at baseline but also 
for major (other than stroke) HR-QoL determinants [19–
24]. Because periprocedural stroke, similar to that within 
the follow-up period, has a negative impact on HR-QoL 
[13], subjects with any stroke during follow-up (or with 
any other major adverse clinical event) were not includ-
ed in an analysis aimed to evaluate the “clean” effect of 
either of the CS revascularization methods on the quality 
of life. To control for the subject’s ability to adequately 
express their views, the present analysis was limited to 
patients with cerebral infarct location in the non-dom-
inant hemisphere (for study group homogeneity, only 
those with left-dominant hemisphere and right-hemi-
spheric stroke were considered).
The nearest neighbour search algorithm [25] was ap-
plied to identify similar patient pairs (CEA-CAS), matched 
for National Institutes of Health Stroke Scale (NIH-SS) 
score as well as presence of major known determinants 
of HR-QoL other than stroke including age and sex, edu-
cational and marital status, hypertension, diabetes, and 
the presence of heart failure [19–24].
The study was approved by the local Ethics Commit-
tee, and all subjects provided informed written consent. 
Statistical analysis
The results were presented separately for the CAS 
and CEA cohort. Differences between qualitative vari-
ables were calculated using the c2 test. For eight 
SF-36 domains the total score for all measurement points 
(baseline, after 2 weeks, 6 months and 12 months) was 
presented as the mean with 95% CI for the mean. In 
each study cohort, differences between the time points 
were checked with one-way repeated measures ANOVA, 
whereas differences between the CAS and CEA cohort 
were checked by the t-paired test for all measurement 
points separately. For all analyses, p-values of < 0.05 for 
two-sided tests were considered statistically significant. 
All calculations were carried out using IBM SPSS Statis-
tics 24.
Results
The nearest neighbour search identified, amongst 
667 carotid revascularization subjects who returned 
completed SF-36 questionnaires by 12 months after the 
procedure, 42 (CEA-CAS) pairs of left hemispheric-domi-
nant survivors of right hemispheric stroke who – besides 
the degree of neurologic impairment as per the NIH-SS 
 – could be matched for age, sex, marital and education-
al status, hypertension, heart failure and diabetes, and 
who (1) underwent an uneventful carotid revasculariza-
tion procedure, (2) had no major adverse clinical events 
throughout 12 months, and (3) completed the SF-36 
questionnaire (i) within 7 days before, (ii) 14 days after, 
(iii) 6 months after, and (iv) 12 months after carotid re-
vascularization. 
Clinical characteristics of the CEA and CAS cohort are 
provided in Table I. 
The HR-QoL results are given for CEA vs. CAS re-
spectively. At baseline, HR-QoL perception was low and 
was similar in both groups (30.8 ±4.6% vs. 29.1 ±3.9%, 
CEA-CAS difference of 1.7 ±0.9%; p = 0.68). Hospital-
ization length was significantly higher in the CEA group 
(p < 0.001). Evolution of the HR-QoL total score is shown 
in Figure 1. 
The CS revascularization was associated with a ma-
jor HR-QoL improvement that was significantly greater 
in CAS than in CEA at 2 weeks after the procedure (60.4 
Mariusz Trystuła et al. Quality of life after CEA and CAS
229Advances in Interventional Cardiology 2019; 15, 2 (56)
±9.2% vs. 71.5 ±6.2%, CEA-CAS absolute difference of 
–11.1 ±1.7% p < 0.001). At 6 months there was a  fur-
ther increase in the HR-QoL score that in each cohort 
was statistically significant both against the baseline val-
ue and against that at 2 weeks. However, at 6 months 
the CEA-CAS difference became significantly narrower 
(70.7 ±9.7% vs. 74.6 ±5.9%, absolute difference of –4.1 
±1.8%; p = 0.026) than 2 weeks after revasculariza-
tion. At 12 months there was no statistically significant 
HR-QoL difference between the study cohorts (72.6 
±6.7% vs. 75.1 ±5.1%, absolute difference of –2.5 ±1.3%; 
p = 0.062), consistent with a similar effect of either CS 
revascularization method on the patient perception of 
their quality of life (Figure 1). 
Analysis of the HR-QoL evolution in the individual 
SF-36 domains (Figure 2) showed that the early CEA-CAS 
difference was driven in the physical health domain by 
a  less bodily pain and better physical functioning and 
role-physical and, in the mental health domain, by high-
er general well-being scores in CAS (p < 0.05 for all). Of 
note, there was no difference between CEA and CAS in 
the role-emotional and vitality domain at 2 weeks. Pa-
tients after CEA reported more frequently difficulties 
with eating/swallowing, neck pain, and headaches but 
less with walking and hemiparetic leg pain. These com-
plaints were associated with the presence of a post-op-
erative neck wound, and sometimes with the formation 
of a subcutaneous haematoma or ecchymosis. The areas 
of  hypoaesthesia were mostly limited to the closest sur-
gical scar area due to damage of the peripheral senso-
ry skin nerve branches. In this case, the complainants 
were mainly men because of the limited superficial sen-
sation in the skin area during shaving, consistent with 
the likelihood of cranial nerve palsy with CEA [11]. In the 
physical functioning domain, patients in the CAS cohort 
complained mainly of difficulties with walking because 








Men 60% (25) 60% (25) –
Women 40% (17) 40% (17)
Age:
Men 70.4 ±5.1 71.3 ±4.1 0.375
Women 73.3 ±4.3 74.3 ±4.7 0.312
Marital status:
Married or with partner 52% (22) 57% (24) 0.660
Alone 48% (20) 43% (18)
Education:
Obtained degree or pro-
fessional qualification
55% (23) 60% (25) 0.660
Unqualified 45% (19) 40% (17)
Hypertension 93% (39) 98% (41) 0.308
Diabetes mellitus 38% (16) 43% (18) 0.660
Coronary artery disease 57% (24) 62% (26) 0.660
Heart failure 19% (8) 31% (13) 0.208
Peripheral vascular disease 52% (22) 57% (24) 0.660
Left dominant hemisphere 100% (42) 100% (42) –
Right hemispheric stroke  
≤ 6 months and RICA  
stenosis ≥ 60% 
100% (42) 100% (42) –
h/o left hemispheric stroke 0% (0) 0% (0) –
Occlusion of LICA* 2.3% (1) 29% (12) < 0.001
CT evidence of right  
hemispheric infarct
100% (42) 100% (42) –
CT evidence of left  
hemispheric infarct
0% (0) 0% (0) –
NIH-SS 5.4 ±2.8 5.9 ±3.1 0.440
RICA – right internal carotid artery, LICA – left internal carotid artery, CT – comput-
ed tomography, NIH-SS – National Institutes of Health Stroke Scale. *Cohorts 
were not matched for the contralateral internal carotid artery patency.
Figure 1. Evolution of total HR-QoL score in sur-
vivors of CS-related stroke, subjected to revascu-
larization with CEA or CAS. Higher scores indicate 
better quality of life. Plotted values at each time 
point represent mean values for the eight SF-36 
domains in each of the two study cohorts and 
associated 95% confidence interval for the mean
CEA – carotid endarterectomy, CAS – carotid artery stenting, SF-36 



















 B/L 2 weeks 6 months 12 months
 CEA         CAS
p < 0.05 vs. baseline
#p < 0.05 CEA vs. CAS
p = 0.062
CEA vs. CAS at 12 month
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of the punctured groin pain. The site of the complaint 
was consistent with the site of the puncture (left or right 
common femoral artery), with a not infrequent haemato-
ma (arterial access site closure devices were barely used 
in the study cohort, and manual compression followed by 
a pressure dressing was routine).
Discussion
Principal findings from this first study to evaluate 
HR-QoL evolution in stroke survivors undergoing carotid 
revascularization by CEA or CAS are the following:
1. Prior to revascularization, HR-QoL scores are very low 
in stroke survivors. 
2. Carotid revascularization – both by CEA and CAS – has 
a major positive impact on patient-reported HR-QoL.
3. In stroke survivors subjected to CEA there is no initial 
post-procedural drop in HR-QoL that was previously 
reported to occur in mostly asymptomatic cohorts 
subjected to CEA.
4. Confounder-controlled analysis demonstrated that 
the early post-revascularization improvement is 
greater with CAS, due to less bodily pain and better 
physical functioning and role-physical in the physi-
cal health domain, and by better role-emotional and 
higher general well-being scores in the mental health 
domain.
5. At 6 months the remaining CEA-CAS difference in 
HR-QoL was small – to become not statistically signif-
icant at 12 months.
The debate on whether and which CS revasculariza-
tion method should be applied to which patient popula-
tions has been focused mainly on (sub-)analyses of ad-
verse clinical event components [4, 11]. In contrast, little 
is known about the quality of life in relation to the two ca-
rotid revascularization methods, particularly in subjects 
with symptomatic CS. In a recent meta-analysis on quality 
of life and functional status after carotid revascularization 
[26] the symptomatic status, surprisingly, was not taken 
into separate consideration. Similarly, in the CREST study, 
which included ≈ 50% symptomatic CS patients, the role 
of the symptomatic status on the quality of life appears 
undetermined [12, 13]. In CREST the overall CAS cohort 
had better outcomes for multiple components of the 
SF-36, with large differences for role-physical, pain, and 
the physical component (all p < 0.01) at both 2 weeks 
and 1 month [13]. On the disease-specific scales, CAS 
patients reported less difficulty with driving, eating/
swallowing, neck pain and headaches but more difficulty 
with walking and leg pain (all p < 0.05) [13]. However, at 
1 year there were no differences in any HR-QoL measure 
between CAS and CEA [13]. This line of findings is, in gen-
eral, confirmed in our study focused specifically on stroke 
survivors with CS. 
In stroke survivors with different stroke pathomecha-
nisms, quality-adjusted survival is very low over 5 years 
after stroke [1]. Stroke often causes impairment of phys-
ical, cognitive, emotional, behavioural, and social func-
tions, negatively affecting the quality of life [14]. Patients 
with symptomatic CS have been reported to exhibit sig-
nificantly poorer HR-QoL than the general population [14, 
27]. Our study cohorts exhibited, at baseline, extreme-
ly low HR-QoL – lower than reported in other studies of 
symptomatic patients and lower than might be consid-
ered to be expected (Figure 1). However, other studies 
 Physical  Role Bodily General Vitality Social Role Well
 functioning physical pain health  functioning emotional being
Figure 2. Evolution of HR-QoL scores in each of the eight SF-36 domains in survivors of CS-related stroke, sub-
jected to revascularization with CEA or CAS. Higher scores indicate better quality of life. Bars represent mean 
values for each SF-36 domain in the two study cohorts at each time point



































*p < 0.05 vs. baseline, #p < 0.05 CEA vs. CAS for each of the 8 SF-36 domains, the 4 bars show sequentially 
the mean score at baseline, 2 weeks, 6 months and 12 months.
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have included, in the symptomatic cohorts, patients with 
transient ischaemic attacks the impact of which on HR-
QoL is significantly smaller than that of stroke [1, 28]. 
Also, the stroke victims in the present study had a sub-
stantial neurological deficit (Table I). This low baseline 
HR-QoL level (Figure 1) may explain why, in contrast to the 
general expectation of an initial decline in HR-QoL after 
CEA [26], the CEA cohort in our study showed an increase 
HR-QoL after the procedure (Figure 1). The post-proce-
dural increase in HR-QoL, however, was significantly 
smaller in the CEA cohort than in CAS patients (Figure 1), 
likely including the initial drop reported for mixed (as-
ymptomatic and symptomatic) CEA groups [26]. 
Presentation with stroke has been suggested, by 
some, to predict poor outcomes after CEA [27], a finding 
not confirmed by data from the present study in relation 
to HR-QoL, with average scores, at 12 months, at the level 
of 70–75% (Figure 1). The magnitude of the improvement 
seen in the present study is consistent with the mean 
increase in patients’ quality of life evaluated previously 
in the Polish population using a 10-point Likert scale (in-
crease from 3.9 to 6.3 points after CEA, p < 0.001) [29]. 
Indeed, our data are also consistent with the prior find-
ing by the Oxford group that patients with symptomatic 
carotid artery disease undergoing an uncomplicated CEA 
perceive improved quality of life and overall health [7]. 
In the present investigation, by performing a matched-
pair analysis with the maximally close-to-each-other 
CEA-CAS patient pairs identified using a nearest neigh-
bour search algorithm [25], we controlled not only for the 
severity of neurologic impairment after stroke but also 
for major HR-QoL determinants (Table I). The guidelines 
and vascular surgery clinical practice favour CAS in high-
er surgical risk patients, such as those with heart failure 
or contralateral internal carotid artery (ICA) occlusion [4]. 
Accordingly, the CAS cohort in this study included numer-
ically more patients with heart failure (31% vs. 19%, p = 
0.208, Table I) and more subjects with contralateral ICA 
occlusion (2.4% vs. 28.6%, p < 0.001, Table I) despite our 
maximized optimal pair (CEA-CAS) match. Nevertheless, 
CAS patients reported a better overall quality of life at 
2 weeks and 6 months after the procedure than those 
managed with CEA (Figure 1). 
Strengths
One fundamental strength of this work is our unique 
investigational approach minimizing, in the evaluation of 
the relative value of CEA and CAS for the quality of life 
after carotid revascularization in stroke victims, the role 
of HR-QoL determinants other than the ischaemic brain 
infarct (Table I). Another is that by limiting the study sub-
jects to those with non-dominant hemisphere stroke (Ta-
ble I), we minimized the effect of stroke on the subject’s 
ability to adequately express the detailed HR-QoL charac-
teristics required by the SF-36 questionnaire. Finally, we 
used the full SF-36 rather than its short version (SF-10) 
or a (limited) 10-point Likert scale (1 – poor to 10 – very 
good; evaluation with scores from 1 to 4 points classified 
as “poor”, from 5 to 7 – “good” and from 8 to 10 – “very 
good”) [29].
Limitations
The present study has several limitations that need 
to be acknowledged. First, our study was cross-sectional 
rather than randomized and (despite the very large base-
line sample) the volume of matched pairs may be consid-
ered moderate. Secondly, we controlled for several ma-
jor (Table I) but not all HR-QoL determinants other than 
ischaemic stroke. It is thus possible that conditions such 
as arthritis [23, 30] or lung disease [23, 31] could bias 
our findings of the effect of CEA vs. CAS on patient-re-
ported HR-QoL (Figures 1, 2). Similarly, we were unable 
to take into consideration the effect of exercise [32, 33] 
or lifestyle [24], or that of social support [34] or living 
in a rural versus urban area [35]. Thirdly, it would be of 
interest to learn whether the post-revascularization im-
provement in HR-QoL (Figure 1) is affected by the degree 
of objective improvement as evidenced by the NIH-SS or 
modified Rankin score. Nevertheless, the size of the two 
study cohorts was not sufficient to test the potential re-
lationship between the post-revascularization evolution 
of disability [36] and HR-QoL evolution. Moreover, neuro-
marker release [37] or cranial nerve injury that may occur 
with CEA but not with CAS (and may affect the quality of 
life [11]) was not routinely assessed. Finally, the present 
findings, in relation to HR-QoL after symptomatic CS re-
vascularization using CAS, are applicable only to conven-
tional (i.e., first-generation) carotid stents. The advent 
and increasing penetration of novel carotid stent tech-
nologies, including dual-layer stents that allow reduction 
of peri-procedural complications to ≈ 1% [36, 38, 39] and 
minimize the incremental risk related to the symptomat-
ic status and other risk factors [40], may further impact 
the CEA vs. CAS relative effect on HR-QoL. 
Conclusions
In stroke survivors matched for stroke severity and 
for major HR-QoL determinants beyond stroke, carotid 
revascularization has a  major positive impact on pa-
tient-reported HR-QoL. The early post-revascularization 
improvement is greater with CAS, due to less bodily pain 
and better physical functioning and role-physical as well 
as better role-emotional and higher general well-be-
ing scores. At 6 months the remaining CEA-CAS differ-
ence is small – to become not statistically significant at 
12 months. As surgeons are increasingly performing 
endovascular procedures, these findings may affect – 
on top of major adverse clinical events associated with 
CEA and CAS – the patient and physician preferences, 
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though they require confirmation in larger cohorts and 
multi-centre settings.
In essence, our results show that in survivors of 
CS-related stroke carotid revascularization is associat-
ed with a significant improvement in patient-perceived 
HR-QoL, supporting its use in stroke survivors who were 
not lucky enough to benefit from carotid revasculariza-
tion to prevent the devastating event. 
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